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Converging evidence implicates cerebral white matter changes
(WMC) in the pathogenesis of late-life depression. Overall
progression of WMC has been associated with cardiovascular risk
factors, in particular hypertension and smoking,1–3 and in older
people WMC severity is strongly associated with poorer response
to treatment, development of future depressive symptoms and
worse long-term outcome.4–12 Despite these findings, the
direction of causation between WMC and depression remains
unclear as most studies are cross-sectional; in particular, few
studies have investigated the influence of WMC progression on
depressive outcomes. The possibility still remains that both
WMC and depressive symptoms are manifestations of a common
pathological pathway, or that depressive symptoms pre-date
development of WMC, as they do cardiovascular disease and
stroke.13 The Prospective Study of Pravastatin in the Elderly at
Risk (PROSPER)14 (of people aged 70 years and over, randomised
to statins) found no association between progression of WMC
andeither baseline or incident depressive features, although their
level of baseline WMC were quite low (mean 2ml). In contrast,
the 3C-Dijon study7 (a population-based study of community
dwelling participants aged 65 years and over) demonstrated that
baseline depression was predictive of WMC progression. Further
prospective studies are required to answer this important question
about directionality, which has major implications both for
understanding the aetiology of depression and for informing
appropriate management.
The LADIS (Leukoaraiosis and Disability in the elderly) study
is a large multicentre pan-European longitudinal study of initially
non-disabled older individuals that was established to investigate
the relationship between WMC on magnetic resonance imaging
(MRI) and subsequent development of disability, cognitive
impairment and depression. We have previously reported on
positive associations between baseline WMC and depressive
symptoms in this sample.6,8,15 In this report we examine the
relationship between depression at baseline and progression of
WMC over 3 years, and the relationship between WMC
progression and the development of future depressive symptoms
and new depressive episodes. In line with the vascular depression
hypothesis (that vascular disease changes to the brain predispose
individuals to the development of depression by disrupting fibre
tracts), we hypothesised that progression of WMC would be
associated with the development of depressive symptoms, and
we did not anticipate a relationship between depression at baseline
and WMC progression. Since we hypothesised that the
progression of WMC would precede depressive symptoms, our
primary outcome was depression during year 3. However, we also
looked at the relationship of WMC progression to depression at
any point during the 3-year follow-up.
Method
Sample
Details of the LADIS study have been previously reported.8,16 In
brief, 639 participants were recruited from the 11 European
centres participating in the LADIS study (Amsterdam,
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Background
Brain white matter changes (WMC) and depressive symptoms
are linked, but the directionality of this association remains
unclear.
Aims
To investigate the relationship between baseline and incident
depression and progression of white matter changes.
Method
In a longitudinal multicentre pan-European study
(Leukoaraiosis and Disability in the elderly, LADIS),
participants aged over 64 underwent baseline magnetic
resonance imaging (MRI) and clinical assessments. Repeat
scans were obtained at 3 years. Depressive outcomes were
assessed in terms of depressive episodes and the Geriatric
Depression Scale (GDS). Progression of WMC was measured
using the modified Rotterdam Progression scale.
Results
Progression of WMC was significantly associated with
incident depression during year 3 of the study (P=0.002) and
remained significant after controlling for transition to
disability, baseline WMC and baseline history of depression.
There was no significant association between progression
of WMC and GDS score, and no significant relationship
between progression of WMC and history of depression
at baseline.
Conclusions
Our results support the vascular depression hypothesis and
implicate WMC as causal in the pathogenesis of late-life
depression.
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Copenhagen, Florence, Graz, Go¨teborg, Helsinki, Huddinge,
Lisbon, Mannheim, Newcastle upon Tyne and Paris). At entry
participants were included if they were: (a) aged between 65 and
84; (b) living in the community; (c) non-disabled as assessed by
the Instrumental Activities of Daily Living (IADL) scale (no
impairment at all or only one item compromised);17 (d)
accompanied by an informant; and (e) found to have any degree
of age-related WMC on MRI scan, according to the Fazekas
scale.18 Most participants (n=460) were identified at neurology/
psychiatry clinics, and were discovered to have WMC during their
investigation. The remainder were volunteers from other studies,
or those with incidental findings of WMC on MRI or computed
tomography. Participants were excluded if they had: (a) the
presence of severe physical illnesses; (b) severe unrelated
neurological diseases; (c) leukoencephalopathies revealed by
brain imaging that turned out to be of non-vascular origin; or
(d) severe psychiatric disorders. All procedures were explained
to participants who gave written consent to participate.
As part of the study, all participants had a baseline MRI scan at
their respective centres. The study design was to repeat MRI on all
participants after 3 years. However, MRI scans were not repeated
at one centre (n= 60) due to logistical constraints, leaving 579
possible participants in the study. Repeat magnetic resonance data
were obtained from 394 individuals. Of the remaining 185, 38 had
died, 63 had dropped out of the LADIS study altogether, 5 had
unsatisfactory or missing baseline scans and 79 LADIS
participants refused or were not available for a second scan. The
mean interval between scans was 3.12 years (s.d. = 0.33).
MRI acquisition
All centres used MRI systems with a field strength of 1.5 T, apart
from one centre that had a 0.5 T system. The standard protocol
used for baseline scans16 was repeated. For the white matter
rating, a FLAIR (fluid attenuated inversion recovery) sequence
was acquired with the following parameters: field of view
(FOV)= 250mm, 2566256 or 2566192 matrix, 5mm slice
thickness, 0.5mm slice gap, 19–28 slices, echo time (TE) = 100–
140ms, repetition time (TR) = 6000–10000ms, inversion time
(TI) = 2000–2500ms, echoes per shot 7–24. Volumetric analysis
was performed by a single rater in Amsterdam on a Sparc 5
workstation on Unix (SUN, Palo Alto, California, USA). No
distinction was made between subcortical and periventricular
WMC. Areas of WMC around infarcts and lacunes were
disregarded. Further details of the quantification process are
described elsewhere.19
Progression of WMC was measured at one centre
(Amsterdam) using the modified Rotterdam Progression scale
(absence/presence of progression in nine brain regions).20 Areas
of WMC around infarcts and lacunes were disregarded. We used
the total sum of changes in all regions in order to increase
sensitivity – previous research has shown that cardiovascular risk
factors are associated with progression of total WMC.1–3
Assessment of depressive outcomes
Depressive symptoms were assessed by the self-completed 15-item
Geriatric Depression Scale (GDS).21 The GDS is a self-reported
questionnaire specifically developed as a screening instrument
for the presence of depressive symptoms in older populations.21
Depressive symptoms were assessed at baseline as well as at 3
years. A history of treatment for depression was recorded at
baseline, along with the date of any incident depression over the
follow-up period. History of depression was defined as a past
medical history for a depressive episode requiring treatment (i.e.
prescription of antidepressant medication, psychotherapy,
electroconvulsive therapy) or hospital admission. Incident
depression at each yearly visit was similarly defined as any
depressive episode requiring treatment or hospital admission in
the year preceding the visit. Our primary outcome variable was
a depressive episode in the year preceding the third follow-up
visit. Both history and incident depression were obtained through
a combination of participant interview and evaluation of the case
notes.
Assessment of potential mediators or confounders
All participants had a comprehensive baseline demographic and
clinical assessment administered by trained personnel.
Information was collected on age, gender, education, occupational
status, living conditions and previous medical conditions. Current
smoking status, alcohol intake and physical activity (defined as at
least 30min of physical activity on at least 3 days per week) were
also recorded. Functional status in terms of disability was
measured by means of the IADL scale.17 This is a scale developed
to monitor function and independent living among older adults
and measures a broad set of daily activities including shopping
for personal items, preparing meals, performing housework and
managing personal finances. The Mini-Mental State Examination
(MMSE) was used to assess cognition.22 To increase reliability,
investigators were issued with a specifically designed handbook
that contained guidelines for applying tools. A test of the
interrater, intercentre reliability of IADL scoring showed good
agreement in ratings of each scale item (K statistic ranging from
0.69 to 0.85).23 Participants were re-evaluated on all scales at 1,
2 and 3 years. Transition to disability was defined as the change
from none or one to at least two impaired IADL items.
Statistical analysis
Data were collected in each centre and entered into a central
electronic database on a specifically developed website (www.
unifi.it/LADIS). As GDS, MMSE, WMC and progression of
WMC were not normally distributed, we used non-parametric
statistics – Spearman correlation coefficient and Mann–Whitney
tests for the initial analysis. Binary categorical variables were
analysed using Fisher’s exact test. A binary logistic regression
was used to examine further the relationship between progression
of WMC and depression at 3 years with covariates of possible
confounding variables of age, gender, baseline WMC, MMSE,
transition to disability, baseline depression and study centre.
The significance level was set at P50.05.
Results
Magnetic resonance repeat data were obtained from 394
participants. Table 1 shows the characteristics of participants with
v. without repeat imaging. Those with imaging were on average 2
years younger, had a smaller volume of WMC, higher MMSE and
lower GDS scores. The GDS score did not change on average over
the 3 years in either group.
Those who had a stroke during the study period had a higher
GDS score at 3 years compared with those who did not
(4.7 (s.d. = 3.3) v. 3.0 (s.d. = 2.9), Mann–Whitney Z=73.0,
P= 0.002). There was, however, no difference in depression
incidence at 3 years (7/33 v. 40/355, Fisher P=0.10) or over the
3-year study duration (11/31 v. 78/336, Fisher P=0.13). There
was no significant difference in MMSE decline between those
with depression at 3 years (change MMSE=71.3 (s.d. = 3.9))
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compared with those without depression (change MMSE=70.82
(s.d. = 2.9)).
As Fig. 1 illustrates, progression of WMC was greater in those
with v. without a depressive episode during year 3 (Mann–Whitney
Z= 3.1, P= 0.002; progression of WMC median 2 (IQR= 1:4) v. 1
(IQR= 0:3)). Progression of WMC was also greater in those with
(2 (IQR= 1:3) v. without (1 (IQR= 0:3)) a depressive episode
during years 1, 2 and 3 (Mann–Whitney Z=72.8, P=0.006).
There were no significant differences in progression of WMC
between those with v. without baseline history of depression
(Z= 0.11, P=0.9; median 2 (IQR= 0:3) v. 2 (IQR= 0:3)).
Table 2 shows univariate correlates of the WMC progression.
Greater progression of WMC was associated with greater baseline
WMC, age at baseline, decline in MMSE and lower MMSE at 3
years but not baseline. There were no significant correlations
between progression of WMC and GDS score at baseline or 3
years. Transition to disability over the 3 years was significantly
greater (Fisher’s exact P= 0.008) in those reporting a depressive
episode during year 3 (21/47) v. those not reporting depression
(86/341).
Table 3 shows the results of a multivariate binary logistic
regression of depressive episode during year 3 with variables of
age, gender, body mass index, baseline smoking and alcohol status,
study centre, baseline MMSE, change in MMSE, incident stroke,
baseline WMC volume, baseline history of depression, transition
to disability during the study period and progression of WMC.
This found that significant predictors of depression at 3 years were
baseline history of depression, progression of WMC, baseline
alcohol intake and transition to disability.
Table 4 shows the results of a multivariate binary logistic
regression, with depressive incident during years 1–3, with the
same covariates. In this model, significant predictors of depressive
incident were history of depression, transition to disability,
baseline alcohol intake and study centre.
Discussion
Main findings
The key finding from this study was that progression of WMC
over 3 years predicted incidence of depression at 3 years, even after
controlling for baseline WMC, previous history of depression and
transition to disability over the 3 years. The data are in line with
previous cross-sectional studies showing increased load of WMC
in late-onset depression24 and support the vascular hypothesis25
that vascular disease changes to the brain predispose individuals
to the development of depression by disrupting fibre tracts.
Although incident depression over all 3 years was associated in a
univariate fashion with WMC progression, it was not significant
in the multivariate model. This suggests that progression of
WMC over the 3 years was more strongly associated with
depression at 3 years than during the 3-year period, and fits with
our hypothesis that the WMC precede the depression.
Importantly, we did not find an association between baseline
depression and longitudinal increase in WMC. This is in keeping
with the findings of the PROSPER study14 and with cross-
sectional studies that found no increase in WMC in older
participants with early-onset depression.24 Hence, our findings
suggest that WMC cause late-life depression rather than vice versa.
However, our results are in contrast to those of 3C-Dijon study7
that reported a relationship between baseline depression and
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Table 1 Participant characteristicsa
Total, n Test statistics
Repeat MRI No repeat MRI Repeat MRI No repeat MRI t Mann–Whitney, Z P
Age at baseline, years: mean (s.d.) 73.6 (5.0) 75.4 (5.0) 394 185 3.8 50.001
Gender, female/male 210/184 104/81 394 185 0.53b
Mini-Mental State Examination
Baseline, median (range) 28 (16–30) 27 (18–30) 394 185 75.5 50.001
3 year, median (range) 28 (8–30) 27 (7–30) 385 38 71.3 0.2
Change, mean (s.d.) 70.9 (3.1) 72.1 (6.2) 385 38 72.0 0.044
White matter changes, volume (ml):
median (range) 13.4 (0.76–156) 17.7 (1.13–128) 394 185 72.8 0.005
Geriatric Depression Scalec
Baseline, median (range) 2 (0–14) 2.5 (0–14) 394 185 2.25 0.011
3 year, median (range) 2 (0–14) 2.5 (0–13) 387 36 1.0 0.32
Change, mean (s.d.) 0.16 (2.5) 0.36 (2.5) 387 36 0.5 0.6
History of depression, n (%) 100 (25) 54 (29) 394 185 0.36b
Depressive episode in year 3, n (%) 47 (12) 10 (25) 388 40 0.046b
Stroke during study, n (%) 33 (9) 13 (28) 389 47 0.001b
MRI, magnetic resonance imaging.
a. At 3 years, there were 101 participants who had dropped out or died. Of the 84 who refused or were unsuitable for MRI a full interview was only completed for 36 participants.
b. Fisher’s exact test.
c. For Geriatric Depression Scale the maximum score is 15.
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Table 2 Univariate correlations of progression of white matter changes
Variable n Spearman, rho P
Age at baseline 394 0.12 0.019
Gender 394 70.05 0.34
White matter changes, volume 387 0.48 50.001
Baseline Mini-Mental State Examination 394 0.01 0.84
Baseline Geriatric Depression Scale 394 0.05 0.37
3-year Mini-Mental State Examination 385 70.12 0.015
3-year Geriatric Depression Scale 387 0.06 0.26
3-year change in Geriatric Depression Scale 387 0.02 0.77
3-year change in Mini-Mental State Examination 385 70.17 0.001
Body mass index 394 70.04 0.38
Smoker at baseline 394 0.09 0.08
Alcohol at baseline, g/day 205 0.09 0.21
Physical activity at baseline, yes/no 394 0.00 0.96
Table 3 Binary logistic regression of depressive episode during year 3 (n = 23/198)
Wald P Hazard ratio (95% CI)
Age 1.03 0.31 0.94 (0.82–1.07)
Female 0.01 0.94 1.06 (0.23–4.83)
Baseline WMC, volume 0.28 0.60 0.82 (0.38–1.74)
Transition to disability 6.42 0.011 8.43 (1.57–45.35)
History of depression at baseline 6.88 0.009 7.61 (1.62–35.76)
Incident stroke 2.70 0.10 4.50 (0.72–28.09)
MMSE baseline 1.03 0.31 0.87 (0.66–1.14)
3-year change in MMSE 0.01 0.92 1.01 (0.83–1.24)
Body mass index baseline 0.01 0.91 1.01 (0.84–1.22)
Physical activity 0.03 0.87 1.17 (0.18–7.83)
Smoking baseline 2.89 0.089 0.13 (0.01–1.43)
Alcohol baseline, g/day 5.99 0.014 1.05 (1.01–1.09)
Progression of WMCa 3.90 0.048 1.41 (1.00–2.00)
Study centre 11.69 0.23
WMC, white matter changes; MMSE, Mini-Mental State Examination.
a. Progression of WMC using the Rotterdam Progression scale.
Table 4 Binary logistic regression of depressive episode during year 1+2+3 (n = 41/188)
Wald P Hazard ratio (95% CI)
Age 0.71 0.40 1.04 (0.95–1.15)
Female 0.04 0.84 1.12 (0.36–3.53)
Baseline WMC, volume 0.22 0.64 1.14 (0.66–1.97)
Transition to disability 6.47 0.011 5.14 (1.42–18.6)
History of depression at baseline 14.58 50.001 8.12 (2.71–24.3)
Incident stroke 0.26 0.61 1.50 (0.30–7.57)
MMSE baseline 0.96 0.33 0.89 (0.70–1.13)
3-year change in MMSE 0.26 0.61 0.96 (0.80–1.14)
Body mass index baseline 1.01 0.31 1.08 (0.93–1.25)
Physical activity 0.09 0.77 0.82 (0.22–3.06)
Smoking baseline 0.84 0.36 0.46 (0.09–2.49)
Alcohol baseline, g/day 4.73 0.030 1.03 (1.00–1.06)
Progression of WMCa 0.00 0.97 0.99 (0.74–1.34)
Study centre 20.09 0.017
WMC, white matter changes; MMSE, Mini-Mental State Examination.
a. Progression of WMC using the Rotterdam Progression scale.
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WMC progression. The demographics of the study populations
may underlie the differences. Unlike the electoral roll-based Dijon
study, our study was of non-disabled community dwellers who
were selected as they already had WMC. In keeping with other
studies,26 we found baseline WMC a strong predictor of WMC
progression. Hence pre-existing vascular disease is likely to be a
major cause of WMC progression in our study.
Our findings of progression of WMC predicting future
episodes of depression are contrary to the longitudinal PROSPER
study.14 Again, the discrepancy may be due to differences in the
cohorts studied. The PROSPER study had much lower WMC load
(2ml v. our 15ml) and had lower incidence of depression, and
hence the WMC burden may not have been sufficient to detect
an increase in the incidence of depressive features. Our results
are, however, in line with a study of older participants with
depression at baseline,11 in which poorer outcome of depression
was associated with progression of WMC, but not baseline levels
of WMC.
We did not find a relationship between WMC progression and
depressive symptoms as measured by the self-reported GDS. Since
our definition of incident depression was that the participant
received treatment, it is possible that effective treatment for
depressive symptoms may have reduced GDS scores when they
were recorded. Alternatively, those with worse depressive
symptoms at the time of follow-up may have been more likely
to decline participation.
There was a significant effect of study centre on depression
over 3 years. Since the centres were heterogeneous in terms of their
clinical focus (neurology, psychiatry, stroke clinics, etc.) and also
culturally due to the pan-European nature of the LADIS study,
it seems possible that this effect was as a result of the differing
nature of the recruited population at each centre. Alcohol use at
baseline was associated with depressive incidents during the study.
The associations between alcohol and depression are bidirectional,
with alcohol often being used by people with depression, but also
leading to the development of depression.27
We have demonstrated a significant association between
progression of WMC over 3 years, and depression at 3 years,
controlling for a number of confounding variables. However, it
is difficult to unambiguously identify a direct causal relationship
between WMC and depression, because of the interlinking
relationships between cardiovascular disease, disability, cognitive
problems and depression. For example there are established
associations between WMC and both cognitive decline28 and
reduced daily physical functioning,29 and both of these in turn
have links to depressive features.
Strengths and limitations
Limitations of the study are the use of a rating scale to assess
WMC progression, rather than volumetric analysis, although the
Rotterdam Progression scale has been widely used and is reliable
and sensitive to change.30 We chose to use this scale for measuring
progression, since we were not aware of any volumetric methods
that had been validated in a multicentre setting, and we were
concerned that the volumetric measurement might be too
dependent on the MRI sequence used at the different locations.
There was some participant attrition over the study period that
may have affected the results, but our attrition rate is not
uncommon for studies of this size and duration in older people.
Arguably, those who developed depression would have been more
likely to drop out, and thus if anything, the attrition rate possibly
tended to reduce the significance of our findings.
Our measurement of incident depression was a depressive
episode that had resulted in treatment or admission to hospital.
Thus, we may have missed some cases in which the participant
did not seek treatment for their illness. There may also have been
lack of specificity in the diagnosis, as we did not use a standard
procedure for depression (for example DSM-IV31). However, the
advantage of our approach is that it should capture incidents of
depression occurring at any point over the study period, rather
than just at the time of assessment.
The strengths of the study are the large, multicentre, pan-
European design and the size of the population, all of which
increase the generalisability of the findings. We used a
standardised imaging protocol, and obtained repeat imaging using
the same protocol at 3 years. Analysis of scans was centralised and
undertaken masked to all clinical outcome data. Unlike other
studies, our comprehensive assessment package allowed us to
investigate key potential confounds, such as the development of
disability and cognitive impairment, which might possibly
mediate the relationship between progression of WMC and future
depression.
Implications
In conclusion, we found evidence that progression of WMC is
associated with incidence of depression, even when controlling
for other factors. Our previous reports have found an association
between WMC at baseline and future depression, and we found no
evidence of the reverse association between depression at baseline
and future progression of WMC. Our results therefore support the
vascular hypothesis of depression and are consistent with WMC
pre-dating and playing a key aetiological role in the development
of depression in older people. Trials of antihypertensive drugs
have demonstrated that successful blood pressure control reduces
progression of WMC.32,33 Reducing white matter lesion
progression by means of control of vascular risk factors should
thus be investigated as a potentially important strategy in treating
older people with, or at risk of, depression.
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